ALRN News and Press, Aileron Therapeutics Inc. From 05/01/24

AUSTIN, Texas, May 01, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today an...

Low-dose LTI-03 (2.5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and increased the expression of a biomarker indicative of epithelial health, suggesting potential therapeutic effect Posi...

2024-04-18 12:42:59 ET More on Mid-day movers & stocks. Canopy Growth Is Climbing, But It Won't Last Canopy Growth Corporation (CGC) Q3 2024 Earnings Call Transcript Canopy Growth: Reiterate Strong Sell, Dilutive Offering Likely First Of Many To Come Cano...

Aileron Therapeutics, Inc. (NASDAQ: ALRN) is one of today's top gainers. The company's shares have moved 29.53% on the day to $5.5. Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Ph...

A look at the top 10 most actives in the United States SiNtx Technologies Inc. (SINT) rose 73.2% to $0.0646 on volume of 191,555,690 shares AGBA Group Holding Limited (AGBA) rose 245.0% to $1.38 on volume of 41,065,125 shares TIAN RUIXIANG Holdings Ltd (TIRX) rose 135.2% to $1.14 on volum...

2024-04-18 10:00:26 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Short interest in S&P 500 health stocks rises, Moderna among m...

2024-04-16 09:52:53 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Aileron Therapeutics (NASDAQ: ALRN ) just reported results for the fourth quarter of 2023. Aileron Therapeutics reported earnings per share of -$1.54. The company did ...

2024-04-16 03:25:41 ET More on Aileron Therapeutics Seeking Alpha’s Quant Rating on Aileron Therapeutics Historical earnings data for Aileron Therapeutics Financial information for Aileron Therapeutics Read the full article on Seeking Alpha For...

Topline results from Phase 1b study of LTI-03, a novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected to be reported in the third quarter of 2024 Cash runway expected to fund operations and key milestones into the fourth quarter of...

GD Culture Group Limited (GDC) is expected to report for Q4 2023 Citizens Inc. Class A ($1.00 Par) (CIA) is expected to report for quarter end 2023-12-31 Escalade Incorporated (ESCA) is expected to report for Q4 2023 Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31...